Zusammenfassung
Der Prozeß der Tumorneoangiogenese beschreibt die Neubildung von Gefäßen, die zur Homöostase eines neoplastischen Zellverbandes notwendig sind.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Barlogi B (2000) Thalidomide in the management ofmultiplemyeloma: the Arkansas experience in >300 patients with single agent and combination chemotherapy. Proc Am Soc Clin Oncol 19: abstr. 28
Batist G, Champagne P, Hariton C et al (2002) Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. Proc Am Soc Clin Oncol 21: abstr.
Bramhall SR, Rosemurgy A, Brown PD et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447–3455
Bruns CJ, Shrader M, Harbison MT et al (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastases and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101–108
Cao Y (1999) Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica 84:643–650
Dupont J, Camastra D, Gordon MS et al (2003) Phase I study of VEGF trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 22: abstr. 776
Eder JP, Supko JG, Clark JW et al (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772–3784
Escudier B, Venner P, Buckowski R et al (2003) Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol 22: abstr. 844
Fiedler W, Mesters R, Tinnefeld H et al (2003) A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102:2763–2767
Giles FJ, Stopeck AT, Silverman LR et al (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with acute myeloid leukaemia or myelodysplastic syndromes. Blood 102:795–801
Hurwitz H, Fehrenbacher L, Cartwright T et al (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22: abstr. 3634
Johnsson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22:2184–2191
Kabbinavar F, Hurwitz H, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil(FU)/ leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65
Kindler HL, Ansari R, Lester E et al (2003) Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 22: abstr. 1037
Kühnen BC, Rosen L, Smit EF et al (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657–1667
Miller KD, Gradishar W, Schuchter L et al (2002) A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 13:1220–1224
Miller KD (2004) Recent translational reasearch: antiangiogenic therapy for breast cancer — where do we stand? Breast Cancer Res 6:128–132
Pedley RB, Hill SA, Boxer GM (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-o-phosphate. Cancer Res 61:4716–4722
O’Reilly MS, Holmgreen L, Shing Y et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328
Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906–3927
Shimada Y, Imamura M, Watanabe G et al (1999) Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Cancer Res 80(8):1281–1288
Singhal S, Mehta J (2003) Novel therapies inmultiplemyeloma. Int J Hematol 77:226–231
Smylie M, Mercier R, Aboulafia D et al (2001) Phase III study of the matrix metalloprotease inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20: abstr. 1226
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434
Zhang L, Yu D, Hicklin DJ et al (2002) Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 62:2034–2042
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schleucher, N., Vanhoefer, U. (2006). Inhibition der Tumorangiogenese und Neoangiogenese. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_48
Download citation
DOI: https://doi.org/10.1007/3-540-31303-6_48
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20657-6
Online ISBN: 978-3-540-31303-8
eBook Packages: Medicine (German Language)